A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Healthy Young and Elderly Japanese Volunteers After Oral Single and Multiple Ascending Doses.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2010
At a glance
- Drugs AZD 1446 (Primary)
- Indications Alzheimer's disease; Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors AstraZeneca
- 09 Jun 2010 Additional lead trial investigator (Shunji Matsuki) identified as reported by ClinicalTrials.gov.
- 09 Jun 2010 Actual patient number (97) added as reported by ClinicalTrials.gov.
- 09 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.